Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Receivables - Net: 2019-2021

Historic Receivables - Net for 4D Molecular Therapeutics (FDMT) over the last 3 years, with Dec 2021 value amounting to $47,000.

  • 4D Molecular Therapeutics' Receivables - Net fell 96.84% to $47,000 in Q4 2021 from the same period last year, while for Dec 2021 it was $47,000, marking a year-over-year decrease of 96.84%. This contributed to the annual value of $47,000 for FY2021, which is 96.84% down from last year.
  • Per 4D Molecular Therapeutics' latest filing, its Receivables - Net stood at $47,000 for FY2021, which was down 96.84% from $1.5 million recorded in FY2020.
  • In the past 5 years, 4D Molecular Therapeutics' Receivables - Net registered a high of $1.5 million during FY2020, and its lowest value of $47,000 during FY2021.
  • Its 3-year average for Receivables - Net is $837,000, with a median of $978,000 in 2019.
  • As far as peak fluctuations go, 4D Molecular Therapeutics' Receivables - Net surged by 51.94% in 2020, and later crashed by 96.84% in 2021.
  • Yearly analysis of 3 years shows 4D Molecular Therapeutics' Receivables - Net stood at $978,000 in 2019, then spiked by 51.94% to $1.5 million in 2020, then crashed by 96.84% to $47,000 in 2021.